A network approach to developing immuno-oncology combinations in Canada

Immune checkpoint inhibitors have revolutionized care for many cancer indications, with considerable effort now being focused on increasing the rate, depth, and duration of patient response. One strategy is to combine immune strategies (for example, ctla-4 and PD-1/L1–directed agents) to harness add...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Curr Oncol
Prif Awduron: Higenell, V., Fajzel, R., Batist, G., Cheema, P.K., McArthur, H.L., Melosky, B., Morris, D., Petrella, T.M., Sangha, R., Savard, M.F., Sridhar, S.S., Stagg, J., Stewart, D.J., Verma, S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Multimed Inc. 2019
Pynciau:
Practice Guideline
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6476440/
https://ncbi.nlm.nih.gov/pubmed/31043804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4393
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg